What is Lifesci Capital’s Forecast for TARS FY2024 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at Lifesci Capital raised their FY2024 EPS estimates for Tarsus Pharmaceuticals in a research note issued to investors on Thursday, November 14th. Lifesci Capital analyst C. Jubinville now expects that the company will earn ($3.05) per share for the year, up from their previous estimate of ($3.89). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.41) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q4 2024 earnings at ($0.55) EPS.

A number of other equities analysts also recently issued reports on the company. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. The Goldman Sachs Group increased their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday. Finally, Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS opened at $44.83 on Monday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 6.99. The company has a 50 day moving average price of $37.84 and a 200-day moving average price of $32.53. Tarsus Pharmaceuticals has a 1-year low of $15.60 and a 1-year high of $52.99. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -11.77 and a beta of 1.00.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in TARS. Cowen AND Company LLC lifted its position in shares of Tarsus Pharmaceuticals by 3.5% during the 2nd quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock worth $59,725,000 after purchasing an additional 74,855 shares during the last quarter. Jennison Associates LLC lifted its holdings in Tarsus Pharmaceuticals by 47.2% during the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after buying an additional 698,712 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Tarsus Pharmaceuticals by 14.5% during the 1st quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock worth $66,398,000 after buying an additional 231,131 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Tarsus Pharmaceuticals by 7.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock worth $37,536,000 after acquiring an additional 77,825 shares in the last quarter. Finally, Ikarian Capital LLC increased its holdings in shares of Tarsus Pharmaceuticals by 28.7% in the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock valued at $33,886,000 after acquiring an additional 230,000 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.